- Home
- SURG vs NRXP Comparison
SURG vs NRXP Comparison
Compare SURG & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SURG | NRXP |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.6M | 73.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SURG | NRXP |
|---|---|---|
| Price | $1.81 | $2.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $9.50 | ★ $30.50 |
| AVG Volume (30 Days) | 133.3K | ★ 446.3K |
| Earning Date | 11-12-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $50,372,555.00 | $242,000.00 |
| Revenue This Year | $7.13 | N/A |
| Revenue Next Year | $122.51 | $643.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.05 | $1.15 |
| 52 Week High | $3.47 | $6.01 |
Technical Indicators
Market Signals| Indicator | SURG | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 32.06 | 45.23 |
| Support Level | $1.66 | $2.22 |
| Resistance Level | $2.01 | $2.51 |
| Average True Range (ATR) | 0.11 | 0.19 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 25.32 | 68.52 |
Price Performance
Historical ComparisonAbout SURG SurgePays Inc.
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.